Sarepta Therapeutics Inc
Change company Symbol lookup
Select an option...
SRPT Sarepta Therapeutics Inc
AVB AvalonBay Communities Inc
INCY Incyte Corp
MSFT Microsoft Corp
MMM 3M Co
FDX FedEx Corp
CAT Caterpillar Inc
BA Boeing Co
AXP American Express Co
AAPL Apple Inc
Go

Health Care : Biotechnology | Small Cap BlendCompany profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Postmarket

Last Trade
Delayed
$34.35
0.12 (0.35%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$34.23
Day's Change
-1.75 (-4.86%)
Bid
--
Ask
--
B/A Size
--
Day's High
36.23
Day's Low
34.02
Volume
(Light)
Volume:
2,190,942
10-day average volume:
4,137,471
2,190,942
  • Prev Close
    35.98
  • Today's Open
    36.04
  • Day's Range
    34.02-36.23
  • Avg Vol (10-day)
    4.1M
  • Last (time)
    3:59p ET 01/19/17
  • Last (size)
    37
  • 52-Wk Range
    8.00 - 63.73
    LowHigh
  • (04/26/16 - 09/28/16)
    327.88%
  • 131.7%
  • Market Cap
    1.9B
  • Shares Outstanding
    54.6M
  • -5.27
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.8
  • 74.76
  • (% of float 12/30/16)
    18.00

Latest News

Today's News, January 19, 2017
9:08 am ET
MarketWatch
January 11, 2017
9:31 am ET
PR Newswire
January 10, 2017
8:30 am ET
BusinessWire
8:30 am ET
BusinessWire
January 03, 2017
8:30 am ET
BusinessWire
December 30, 2016
5:05 pm ET
BusinessWire
December 22, 2016
8:21 am ET
MarketWatch
December 19, 2016
5:23 pm ET
BusinessWire
December 06, 2016
7:15 am ET
PR Newswire
November 30, 2016
6:00 pm ET
BusinessWire
November 17, 2016
9:28 am ET
MarketWatch
November 04, 2016
8:30 am ET
BusinessWire
October 31, 2016
5:30 pm ET
BusinessWire
October 28, 2016
8:35 am ET
Zacks
October 27, 2016
7:00 am ET
BusinessWire
October 24, 2016
8:30 am ET
BusinessWire
October 08, 2016
2:46 pm ET
MarketWatch
October 07, 2016
11:23 am ET
MarketWatch
11:10 am ET
MarketWatch
October 04, 2016
4:10 pm ET
MarketWatch
7:58 am ET
MarketWatch
7:49 am ET
MarketWatch
7:49 am ET
MarketWatch
7:48 am ET
MarketWatch
September 30, 2016
1:28 pm ET
MarketWatch
1:28 pm ET
MarketWatch
September 28, 2016
10:26 am ET
MarketWatch
September 21, 2016
4:16 pm ET
MarketWatch
4:03 pm ET
MarketWatch
4:03 pm ET
MarketWatch
4:02 pm ET
MarketWatch
8:23 am ET
MarketWatch
September 20, 2016
3:56 pm ET
MarketWatch
8:29 am ET
MarketWatch
September 19, 2016
3:54 pm ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2017 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , and

Copyright © 2017. All rights reserved.